TG Therapeutics, Inc. (TGTX) Earnings History
Annual and quarterly earnings data from 1996 to 2024
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 88.3% | 12.7% | 7.1% |
| 2023 | 94.0% | 8.8% | 5.4% |
| 2022 | 90.5% | -7839.0% | -8036.3% |
| 2021 | 88.2% | -5154.3% | -5204.1% |
| 2020 | 100.0% | -179996.1% | -183803.3% |
Download Data
Export TGTX earnings history in CSV or JSON format
Free sign-in required to download data
TG Therapeutics, Inc. (TGTX) Earnings Overview
As of March 1, 2026, TG Therapeutics, Inc. (TGTX) reported trailing twelve-month net income of $60M, reflecting +0.8% year-over-year growth. The company earned $0.37 per diluted share over the past four quarters, with a net profit margin of 0.1%.
Looking at the long-term picture, TGTX's historical earnings data spans multiple years. The company achieved its highest annual net income of $23M in fiscal 2024, representing a new all-time high.
TG Therapeutics, Inc. maintains positive profitability with a gross margin of 0.9%, operating margin of 0.1%, and net margin of 0.1%. The company continues to generate positive earnings from operations. View revenue history →
Compared to industry peers including ARGX ($923M net income, 0.4% margin), CANF (-$9M net income, -11.7% margin), AKTX (-$16M net income), TGTX has room to improve margins relative to the peer group. Compare TGTX vs ARGX →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
29 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $23M | +84.5% | $42M | $0.15 | 7.1% | 12.7% |
| 2023 | $13M | +105.7% | $21M | $0.09 | 5.4% | 8.8% |
| 2022 | -$224M | +35.7% | -$218M | $-1.46 | -8036.3% | -7839.0% |
| 2021 | -$348M | -24.6% | -$345M | $-2.63 | -5204.1% | -5154.3% |
| 2020 | -$279M | -61.6% | -$274M | $-2.42 | -183803.3% | -179996.1% |
| 2019 | -$173M | +0.4% | -$169M | $-1.96 | -113730.9% | -111220.4% |
| 2018 | -$173M | -46.4% | -$174M | $-2.30 | -114132.9% | -114736.8% |
| 2017 | -$118M | -51.4% | -$119M | $-1.91 | -77749.9% | -77904.6% |
| 2016 | -$78M | -24.3% | -$79M | $-1.60 | -51353.4% | -51823.5% |
| 2015 | -$63M | -12.8% | -$63M | $-1.38 | -41310.0% | -41461.9% |
See TGTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TGTX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare TGTX vs AGIO
See how TGTX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is TGTX growing earnings?
TGTX EPS of $0.37 reflects slowing growth at +0.8%, below the 5-year CAGR of N/A. TTM net income is $60M. Expansion rate has moderated.
What are TGTX's profit margins?
TG Therapeutics, Inc. net margin is +0.1%, with operating margin at +0.1%. Below-average margins reflect competitive or cost pressures.
How consistent are TGTX's earnings?
TGTX earnings data spans 1996-2024. The current earnings trend is +0.8% YoY. Historical data enables comparison across business cycles.